PainChek Share Purchase Plan Results

PainChek Ltd (ASX: $PCK) has announced the initial results of its Share Purchase Plan (SPP), which closed oversubscribed on 4th March 2024, targeting $2,500,000. The final number of shares to be issued will be disclosed on 11th March 2024.

PainChek CEO and Managing Director's Comments on SPP Results

On behalf of the directors we thank all our shareholders who participated in the SPP. It was a great show of support and a strong endorsement of the positive commercial progress the Company has achieved to date. This additional capital helps to provide the Company with the platform to deliver on the global market opportunities and planned growth.

Summary of PainChek's Share Purchase Plan and Future Outlook

PainChek Ltd (ASX: $PCK) has successfully closed its Share Purchase Plan (SPP) oversubscribed, indicating robust shareholder confidence and support in the Company's commercial advancements. The additional capital raised through the SPP will enable PainChek to further pursue global market opportunities and planned growth. With its innovative pain assessment and monitoring application, PainChek continues to make significant strides in best-practice pain management for individuals across various environments. The Company's regulatory clearances and contracts with numerous aged care facilities reflect its commitment to addressing the critical need for accurate pain assessment and management. PainChek's expansion into home care further underscores its dedication to providing comprehensive pain management solutions. As PainChek progresses, its focus on leveraging technology to enhance pain assessment and management for diverse demographics positions it for continued success in the global healthcare landscape.